Abstract
Fig. S1: PFS analysis of the BsAb vs other bridging groups. Fig. S2: Quantification of CAR-T cells using MFC vs PCR. Fig. S3: Correlation of sBCMA levels with IMWG response criteria. Fig. S4: PFS analysis of patients with higher vs lower than median sBCMA on the day of CAR-T infusion. Fig. S5: Impact of bridging with BsAb vs other BT groups on absolute counts of T cell subsets. Fig. S6: Absolute numbers of CAR-T cells in the bridging groups. Fig. S7: Proportions of CAR-T cells in the samples used for the in vitro cytotoxicity assay per bridging group. Fig. S8: Proportions of naive and memory Tregs in the bridging groups. Fig. S9: Overview of T cell subsets stratified by response to bridging. Fig. S10: Alluvials of T cell subsets among the bridging groups. Fig. S11: Checkpoint marker expression stratified by response to bridging therapy. Fig. S12: Proportions of PD-1+CD4+ and PD-1+CD8+ non-transduced T cells amongst the bridging groups. Fig. S13: Overview of sample numbers in the bridging groups included for single-cell multi-omics sequencing. Fig. S14: Numbers of circulating plasma cells.